Some breast cancer tumors may be resistant to a common chemotherapy treatment

Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Principal investigator Ing Swie Goping and her team discovered some breast had low levels of certain , and that those tumours didn't respond well to taxane , a common treatment used in breast cancer.

"These tumours didn't shrink and were resistant to a common . These results give us a strong incentive to continue our research," she said.

Goping and her team looked at tumour samples from 24 patients who had breast cancer. These patients were treated with chemotherapy before surgery. The team discovered four genes in the 'survival' system of tumour cells weren't functioning well in some of the samples. When parts of this system don't work the way they are supposed to, the tumour survival system gets weaker.

Researchers expected that because this survival system was weaker in some tumours, that chemotherapy treatment would be more effective at shrinking these tumours. But the opposite happened.

Instead, they found that the stronger the tumours' survival system was, the better the chemotherapy worked.

"This discovery was a bit of a surprise," said Goping, a researcher in both the Department of Biochemistry and the Department of Oncology.

"One would expect that with strong survival systems would be more chemotherapy-resistant, but that's not what we discovered."

Goping noted this research was purely curiosity-driven, and the finding underscores the importance of basic research.

"It was a question we were asking at a very basic level and it turns out the discovery could be clinically relevant. At the moment there is no tool to determine which women would be good candidates for taxane chemotherapy. And chemotherapy resistance is a major clinical problem."

Goping hopes to continue this research by examining tumour samples from thousands of patients over a span of at least three years, in hopes of confirming what the team discovered is indeed a 'marker' that will predict which breast cancer patients will respond well to taxane chemotherapy.

She noted it would be years before doctors would be able to actually start testing patients for this marker.

More information: The study was published in the peer-reviewed journal Oncogene.

Related Stories

Genes associated with aggressive breast cancer

Aug 16, 2010

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment ...

Discovery may help fight late-stage ovarian cancer

Nov 16, 2011

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often ...

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

9 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

13 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments